Regenovue Non-Lidocaine: Regulatory Status and Professional Sourcing Guide

Regenovue Non-Lidocaine is a hyaluronic acid (HA) dermal filler manufactured by NeoGenesis Co., Ltd., based in South Korea. It is designed for professional aesthetic applications. As a non-lidocaine formulation, it caters to specific patient preferences or clinical requirements where local anesthetic is administered separately or not needed. This product represents one option within the broader category of Hyaluronic acid dermal filler catalog available for professional procurement.

The regulatory landscape for medical devices, including dermal fillers, varies significantly by region. Key certifications often include:

• KFDA (South Korea Food and Drug Administration): As a product of NeoGenesis Co., Ltd., based in South Korea, Regenovue Non-Lidocaine holds KFDA approval for domestic sale and serves as a foundational certification for international export. [VERIFY: KFDA approval status for Regenovue Non-Lidocaine]
• CE Mark (Conformité Européenne): The CE Mark is essential for legal distribution within the European Union and the European Economic Area. It signifies compliance with EU safety, health, and environmental protection requirements. Clinics sourcing for EU/UK markets must verify active CE certification. [VERIFY: CE Mark status for Regenovue Non-Lidocaine, including transition to MDR if applicable]
• FDA (U.S. Food and Drug Administration): FDA approval for dermal fillers in the United States is a rigorous process. While a highly regarded benchmark, many international dermal fillers are not explicitly FDA-approved for direct sale in the U.S. market. [VERIFY: FDA approval status for Regenovue Non-Lidocaine in the United States]
• GMP (Good Manufacturing Practice) & ISO 13485: These certifications demonstrate that the manufacturer adheres to international standards for quality management systems in the production of medical devices. Suppliers should be able to provide evidence of these for NeoGenesis Co., Ltd.

Market access for Regenovue Non-Lidocaine depends on specific national health authority registrations beyond the core certifications. Clinics and distributors must confirm local import and distribution legality.

• European Union & UK: Requires CE marking. National competent authorities may have additional notification or registration procedures. The status of products like Regenovue may influence comparative products such as Elasty Plus Non-Lido 2CC in these markets.
• GCC Region (Gulf Cooperation Council): Products typically require registration with local health authorities (e.g., SFDA in Saudi Arabia, MOHAP in UAE). This often necessitates a local authorized distributor.
• LATAM (Latin America): Each country, such as Brazil (ANVISA), Mexico (COFEPRIS), or Colombia (Invima), has distinct registration processes and requirements for medical aesthetics products.
• APAC (Asia-Pacific): Requirements vary widely, from TGA (Australia) and HSA (Singapore) to national drug administrations across other Asian countries. Distributors should confirm specific country registrations.

Parallel importing involves sourcing products from one authorized market for sale in another where it is also authorized but perhaps at a different price point. While legal in some contexts, it introduces complexities regarding traceability, warranty, and regulatory oversight. Clinics must exercise extreme caution. Verifying the legitimacy of the supply chain is paramount, as detailed in guides like Verifying Genuine EPTQ S300.

When sourcing Regenovue Non-Lidocaine, professionals should demand clear documentation. This includes proof of original manufacturer origin, lot numbers, expiration dates, and, critically, any relevant market-specific regulatory approvals applicable to the country of intended use. A comprehensive understanding of Hyaluronic Acid Dermal Filler Market Trends: Insights for Ae can also inform sourcing strategies.

For professional buyers, the wholesale pricing for Regenovue Non-Lidocaine is structured to offer volume-based discounts. An illustrative base price is $75.8 per unit. Volume tiers typically apply: orders of 11 units may receive a 4% discount, 21 units a 5% discount, 31 units a 6% discount, and orders of 51 units or more could qualify for an 8% discount. Actual prices may vary by supplier, region, and specific contractual agreements. These figures are provided for general reference and should be verified directly with your chosen wholesale distributor.

Professionals are responsible for ensuring that all aesthetic products stocked meet local regulatory requirements and are sourced ethically. This includes verifying manufacturer certifications, understanding market-specific legalities, and maintaining complete product traceability. An authenticated supply chain helps safeguard patient safety and clinic reputation. Always seek suppliers who can demonstrate clear provenance and provide all necessary documentation for Regenovue Non-Lidocaine.